Tuesday, November 7, 2017
- 9:00AM-11:00AM
-
Abstract Number: 2483
Cycling Versus Swapping in Patients with Rheumatoid Arthritis with an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor: A Systematic Review and Meta-Analysis of Observational Studies
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2740
Cyclophosphamide Treatment Modulates Circulating Cell Populations in Patients with Vasculitis and Autoimmune Systemic Diseases
Vasculitis Poster III: Other Vasculitis Syndromes- 9:00AM-11:00AM
-
Abstract Number: 2507
Dactylitis and Enthesitis Predict Uveitis in Large Axial Spondyloarthropathy Cohort
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2425
Decline in CD8+IFNγ+ Subset but Rise in CD8+IL17+ on Methotrexate Treatment in Rheumatoid Arthritis
Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III- 9:00AM-11:00AM
-
Abstract Number: 2364
Decrease in Cardiovascular Event Excess Risk in Rheumatoid Arthritis Since 2000: A Meta- Analysis of Controlled Studies
Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2153
Decreased Lean Body Mass and Bone Mineral Density but Increased Body Fat in Myositis Patients Are Associated with Disease Duration, Inflammatory Status, Skeletal Muscle Involvement and Physical Activity
Muscle Biology, Myositis and Myopathies Poster- 9:00AM-11:00AM
-
Abstract Number: 2502
Defining Clinically Important Worsening Based on ASDAS-CRP for Axial Spondyloarthritis: A Data-Based Consensus By the Assessment in Spondyloarthritis International Society (ASAS)
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 2020
Definition and Standardization of Inflammatory Pathology in Hand Osteoarthritis Assessed By Ultrasound: Results from a Delphi Process and Reliability Testing in the Omeract Ultrasonographer Group in Hand Osteoarthritis
Imaging of Rheumatic Diseases Poster II- 9:00AM-11:00AM
-
Abstract Number: 2306
Demographic and Clinical Characteristics of Hispanic Children with Juvenile Idiopathic Arthritis: An International, Multicenter Cross-Sectional Study
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis- 9:00AM-11:00AM
-
Abstract Number: 2159
Dermatomyositis Acute Onset/Flares Following Ingestion of Isalean® Herbal Supplement: Clinical and Immunostimulatory Findings
Muscle Biology, Myositis and Myopathies Poster- 9:00AM-11:00AM
-
Abstract Number: 2477
Descriptive Patterns of Switches and Swaps in Patients with Rheumatoid Arthritis Initially Treated with Anti-TNF Agents in First Intention between 2000 and 2006, and 2007 and 2015 – Experience from a Real-World Database RHUMADATA®
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 1997
Detection of Progression of Radiographic Damage Despite Early and Targeted Therapy in Inflammatory Arthritis Using High-Resolution Peripheral Quantitative Computed Tomography
Imaging of Rheumatic Diseases Poster II- 9:00AM-11:00AM
-
Abstract Number: 2286
Determinants of Anti-Tumor Necrosis Factor Drug Use in Juvenile Spondyloarthropathy and Impact on Clinical Disease Outcomes
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis- 9:00AM-11:00AM
-
Abstract Number: 2047
Development and Implementation of a “Data-in-Once” Model for a Pediatric Rheumatology Learning Health System